TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03727451

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: iNO
Description: inhaled nitric oxide

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: iNO
Description: inhaled nitric oxide
Study: NCT00145951

Intervention type: BEHAVIORAL
Intervention: motivational interviewing, brief advice in primary care
Description: motivational interviewing, brief advice in primary care
Study: NCT02705261

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive-behavior therapy
Description: Internet based program to support parents in developing strategies to help their children
Study: NCT01366131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEGF0444A
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Intravenous repeating dose
Study: NCT02513225

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project EMPWR
Description: Participants will receive both Adapted Project EMPWR and Optimized Standard Care (OSC).

Intervention type: OTHER
Group type: OTHER
Intervention: Optimized Standard Care (OSC)
Description: Participants will receive Optimized Standard Care (OSC) alone.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optimized Standard Care (OSC)
Description: Participants will receive Optimized Standard Care (OSC) alone.
Study: NCT01622829

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prescription for Activity and individual instructions
Description: Structured education. Prescription for Activity. This contains an exercise programme which consists of a 30 minutes muscle strengthening exercises to be performed at home at least three times per week and an endurance sports, chosen by the patient, to be performed at least 2 times per week. Additional the physiotherapists advise them in being more active during their individual daily life ( e.g. using a bike for short distances, regular walking, abandon the lift/escalator).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prescription for Activity, without instructions
Description: Prescription with exercise programme. Prescription for activity. This contains an exercise program consisting of 30 minutes of muscle strengthening exercises to be performed at home at least three times per week, the patient also needs to perform in an endurance sport at least two times per week.

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: usual physiotherapy
Description: physiotherapy, treatment as usual
Study: NCT04001036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.5% Xylitol, 0.5% Glucose, and 0.02% L-carnitine
Description: One bag for nocturnal (long-dwell) exchange.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.7% Xylitol, 0.5% Glucose, and 0.02% L-carnitine
Description: One to three, daily (short-dwell) exchanges
Study: NCT04900181

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: the same-day discharge surgery
Description: the same-day discharge surgery is the procedure in which the patient is admitted, operated and discharged within 24 hours.
Study: NCT03878927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-351
Description: CPX-351 is a liposomal formulation of a fixed combination of the antineoplastic drugs cytarabine and daunorubicin. The two drugs are present inside the liposome in a 5:1 molar ratio. The liposome membrane is composed of distearoylphosphatidylcholine, distearoylphosphatidylglycerol and cholesterol in a 7:2:1 molar ratio.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-351
Description: CPX-351 is a liposomal formulation of a fixed combination of the antineoplastic drugs cytarabine and daunorubicin. The two drugs are present inside the liposome in a 5:1 molar ratio. The liposome membrane is composed of distearoylphosphatidylcholine, distearoylphosphatidylglycerol and cholesterol in a 7:2:1 molar ratio.
Study: NCT02609789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-55920839
Description: JNJ-55920839 will be administered as either IV infusion or subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-55920839
Description: JNJ-55920839 will be administered as either IV infusion or subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-55920839
Description: JNJ-55920839 will be administered as either IV infusion or subcutaneous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9 percent (%) normal saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9 percent (%) normal saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9 percent (%) normal saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9 percent (%) normal saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9 percent (%) normal saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9 percent (%) normal saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 0.9 percent (%) normal saline.
Study: NCT00778908

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Late-course accelerated hyperfractionated IMRT
Description: 1. IMRT target definition: PTV1=Gloss tumor PTV; PTV2=High risk area containing subclinical disease; PTV3=Low risk area containing subclinical disease~2. IMRT delivery scheduling: (1) Six-week treatment: PTV1=60Gy/30fractions, PTV2=57Gy/30fractions,PTV3=54Gy/30fractions.(2) Concomitant boost to PTV1 as a second daily treatment for the last 10 treatments of the Six-week treatment: PTV1=12Gy/10fractions.(3) PTV3 will be treated with conventional radiotherapy technique separately.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concomitant cisplatin chemotherapy
Description: cisplatin:40mg/m2 weekly infusion for 6 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Concomitant cisplatin chemotherapy
Description: cisplatin:40mg/m2 weekly infusion for 6 weeks

Intervention type: RADIATION
Group type: OTHER
Intervention: Conventionally fractionated IMRT
Description: IMRT target definition: PTV1=Gloss tumor PTV; PTV2=High risk area containing subclinical disease; PTV3=Low risk area containing subclinical disease IMRT delivery scheduling: (1) Seven-week treatment: PTV1=70Gy/35fractions, PTV2=63Gy/35fractions,PTV3=55.8Gy/31fractions.(2) PTV3 will be treated with conventional radiotherapy technique separately.
Study: NCT01973725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib Hydrochloride
Description: Patients will receive Icotinib Hydrochloride at 125mg/times,oral three times daily for 21 days.
Study: NCT01718444

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progestin
Study: NCT01665274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1,000 mg/m² twice daily, d1-14, q3w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin IV infusion, 130mg/m² d1, q3w
Study: NCT01718444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clomiphene Citrate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene Citrate
Study: NCT02082600

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Description: This group will perform 24 sets of 10 maximum repetitions of eccentric contractions for quadriceps and than will keep awake for 60 hours (2 nights), followed by 1 night of sleep, all inside the lab. During whole protocol, it will be collected several blood samples for evaluation of hormones, cytokines and muscle damage parameters. It will be also evaluated isometric strength and pain.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal sleep
Description: This group will perform 24 sets of 10 maximum repetitions of eccentric contractions for quadriceps and and will be able to sleep the 3 nights. During whole protocol, it will be collected several blood samples for evaluation of hormones, cytokines and muscle damage parameters. It will be also evaluated isometric strength and pain.
Study: NCT03240094

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional telemonitoring
Description: Participants receive a weighing scale, pedometer and television channel in order to perform self measurements and receive guidance on nutrition and physical activity. Nurses use a website in order to receive telemonitoring measurements and decide about proper follow-up. In case of risk of undernutrition, nurses provide personal advice to optimize nutritional status of the participant.
Study: NCT00963794

Intervention type: OTHER
Group type: OTHER
Intervention: Electromagnetic measurement
Description: RC screening was carried out using a Tissue Resonance InterferoMeter probe electromagnetic detector, which consists of a nonlinear oscillator placed in a cylindrical probe about 30 cm long, a radiofrequency spectrum analyzer, and dedicated computer software. Detection of RC is based on the decrease of the electromagnetic signal compared to the mean signal obtained in healthy subjects. The test was performed while the patient stood 120 cm from the receiver. The operator was on the opposite side of the examined pelvis. The detector was kept at close contact to the pelvis surface and was moved through six planes, to obtain a scan of the whole pelvis volume. Based on our previous study, we used the electromagnetic detection system at 465 MHz frequency, in a scale from 0 to 255 arbitrary U.
Study: NCT04000581

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive standard of care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Walk for minimum 30 minutes per day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT01665274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin IV infusion, 130mg/m² d1, q3w
Study: NCT02223078

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G17DT

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Study: NCT03063515

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyridostigmine
Description: single oral dose of 60 mg pyridostigmine tablet
Study: NCT04186754

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Comprehensive functional care plan
Description: The treatment should be carried out INDIVIDUALIZED, in the hospital room or in a conditioned room, in sessions of approximately 30 minutes and on a daily basis. Carried out by professionals in the disciplines of nursing and occupational therapy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional intervention without rehabilitation
Description: Clinical control by nursing professionals and exclusively pharmacological treatment
Study: NCT04032002

Intervention type: OTHER
Group type: OTHER
Intervention: Explorations
Description: On Day 1 vascular fonctions explorations performed

Intervention type: OTHER
Group type: OTHER
Intervention: Explorations
Description: On Day 1 vascular fonctions explorations performed

Intervention type: OTHER
Group type: OTHER
Intervention: Blood samples
Description: On Day 1 35ml taken

Intervention type: OTHER
Group type: OTHER
Intervention: Blood samples
Description: On Day 1 35ml taken
Study: NCT01425268

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AeroForm Tissue Expansion
Description: The AeroForm Patient Controlled Tissue Expander is a breast tissue expander implanted following mastectomy and activated by remote control to release small doses of carbon dioxide from an internal reservoir to fill and inflate the expander.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Saline Tissue Expansion
Description: A saline tissue expander is a breast tissue expander which is implanted following mastectomy and inflated over time using needle injections to fill and inflate the expander with saline.
Study: NCT03726320

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education Counseling Session for PSA Screening
Description: counseling from extensively trained CHW

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Health Counseling Coaching
Description: coaching using an educational tool focused on dietary and lifestyle modification
Study: NCT04323345

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Natural Honey
Description: Natural Honey supplement 1gm/kg/day divided into 2 to 3 doses for 14 days either orally or through nasogastric tube.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: Supportive measures and lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate or Hydroxychloroquine or oseltamivir with or without azithromycin.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Supportive measures and lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate or Hydroxychloroquine or oseltamivir with or without azithromycin.
Study: NCT01125852

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Angiographic embolization
Description: Patients in the intervention arm receive supplementary angiographic embolization within 24 hours from the therapeutic endoscopy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic endoscopy
Description: Patients are treated with standard therapeutic upper endoscopy including endoscopic combination therapy.
Study: NCT01034345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Switch from calcineurin inhibitor maintenance immunosuppression to sirolimus treatment at the doses needed to reach trough blood levels 8-15 ng/mL.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcineurin inhibitor
Description: Patients will maintain the same immunosuppressive regimen based on calcineurin inhibitors. No modifications in the treatment will be conducted.
Study: NCT03783884

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lungpacer Diaphragm Pacing Therapy
Description: Transvenous phrenic nerve stimulation to induce diaphragm contraction.
Study: NCT04366869

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: overdenture
Description: removal of overdenture at night

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: occlusal splint
Description: occlusal splint on overdenture

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox
Description: Botox injection i masseter in temporalis
Study: NCT04749316

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AcuTENS
Description: Stimulation of acupuncture points with TENS machine

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: AcuTENS
Description: Stimulation of acupuncture points with TENS machine
Study: NCT01098019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeomin
Description: Patients will receive Xeomin only at Day 0.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo / Xeomin
Description: Patients will receive 0.9% mL NaCl alone at Day 0. After unblinding (at week 12) patients who were randomized to placebo will receive Xeomin.
Study: NCT00532441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib 150 mg p.o. daily, days 2-7, 9-14, 16-28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib 150 mg p.o. daily, days 2-7, 9-14, 16-28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 30 mg/m2 IV over 30 min weekly x 3 weeks on days 1, 8 and 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 30 mg/m2 IV over 30 min weekly x 3 weeks on days 1, 8 and 15
Study: NCT01723527

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: Clinic-Based Methadone Maintenance Treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: Clinic-Based Methadone Maintenance Treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: Clinic-Based Buprenorphine Maintenance Treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: Clinic-Based Buprenorphine Maintenance Treatment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Employment-based drug abstinence reinforcement
Study: NCT04737226

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: myotonometric assessment
Description: The measurement method of the device is based on the free oscillation technique. Firstly, the probe of the device is placed perpendicular to the skin and a pre-pressure is applied to compress the subcutaneous tissue. Then, a short mechanical impulse is applied, causing damped oscillation on the tissue and the co-oscillation is recorded by an accelerometer.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: myotonometric assessment
Description: The measurement method of the device is based on the free oscillation technique. Firstly, the probe of the device is placed perpendicular to the skin and a pre-pressure is applied to compress the subcutaneous tissue. Then, a short mechanical impulse is applied, causing damped oscillation on the tissue and the co-oscillation is recorded by an accelerometer.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: myotonometric assessment
Description: The measurement method of the device is based on the free oscillation technique. Firstly, the probe of the device is placed perpendicular to the skin and a pre-pressure is applied to compress the subcutaneous tissue. Then, a short mechanical impulse is applied, causing damped oscillation on the tissue and the co-oscillation is recorded by an accelerometer.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ankle mobility assessment
Description: The knee to wall lunge test will use in a standing position while the heel in contact with the ground and the knee was in line with second toe. Athletes will do lunge forward and inclinometer will be place at the middle anterior tibial crista and measurement will be record.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ankle mobility assessment
Description: The knee to wall lunge test will use in a standing position while the heel in contact with the ground and the knee was in line with second toe. Athletes will do lunge forward and inclinometer will be place at the middle anterior tibial crista and measurement will be record.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ankle mobility assessment
Description: The knee to wall lunge test will use in a standing position while the heel in contact with the ground and the knee was in line with second toe. Athletes will do lunge forward and inclinometer will be place at the middle anterior tibial crista and measurement will be record.
Study: NCT03328962

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured smoking cessation counselling based on motivational interviewing (MI) and adapted for the cancer setting eventually combined with provision of smoking cessation medication
Description: structured smoking cessation counselling based on MI and adapted for the cancer setting eventually combined with provision of smoking cessation medication
Study: NCT00781001

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cannabis
Description: 400mg placebo or active cannabis administered via the Volcano vaporizer 1x per study visit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: 400mg placebo or active cannabis administered via the Volcano vaporizer 1x per study visit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: 400mg placebo or active cannabis administered via the Volcano vaporizer 1x per study visit
Study: NCT03878927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-351
Description: CPX-351 is a liposomal formulation of a fixed combination of the antineoplastic drugs cytarabine and daunorubicin. The two drugs are present inside the liposome in a 5:1 molar ratio. The liposome membrane is composed of distearoylphosphatidylcholine, distearoylphosphatidylglycerol and cholesterol in a 7:2:1 molar ratio.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin
Description: Gemtuzumab ozogamicin is a CD-33 directed antibody drug conjugated to calicheamicin. CD 33 is expressed on myeloid leukemic blast cells and on normal hematopoietic cells. The drug is approved for the treatment of newly diagnosed CD 33 positive AML in adults and the treatment of relapsed and refractory CD 33 positive AML in adults. The drug is available for injection 4.5 mg as a lyophilized cake or powder in a single use vial for reconstitution and dilution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin
Description: Gemtuzumab ozogamicin is a CD-33 directed antibody drug conjugated to calicheamicin. CD 33 is expressed on myeloid leukemic blast cells and on normal hematopoietic cells. The drug is approved for the treatment of newly diagnosed CD 33 positive AML in adults and the treatment of relapsed and refractory CD 33 positive AML in adults. The drug is available for injection 4.5 mg as a lyophilized cake or powder in a single use vial for reconstitution and dilution.
Study: NCT02932462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSXS
Description: topical product

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: topical product
Study: NCT02143544

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intra-aortic balloon pump.
Description: Preoperative placement of the intra-aortic balloon pump.
Study: NCT05034016

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Myopic Posterior Scleral Fixation System
Description: Implant HM into the eye through posterior scleral reinforcement